Omeprazole, Furazolidone, and Tetracycline: an eradication treatment for resistant H. pylori in Brazilian patients with peptic ulcer disease

Silva, Fernando Marcuz; Eisig, Jaime Natan; Chehter, Ethel Zimberg; Silva, Júlio Jovino da; Laudanna, Antônio Atílio

doi:10.1590/s0041-87812002000500003

Cited by 16 publications

(24 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Brazil other studies were done with the same antibiotics. Our study presented a side effects rate of 49%, compatible with the scientific literature, which advocates between 34-59.7% [9,10]. In Silva et al [10] the rate of reported side effects for the same therapeutic scheme was 34% 10, while in Machado et al [9] it was 47.2%.…”

Section: Resultssupporting

confidence: 89%

“…The occurrence of side effects, nonetheless, was not the determinant factor for discontinuing the treatment, and able to consider that the proposed therapeutic scheme was welltolerated [9,10]. The therapy proposed for this study avoids using clarithromycin, due to high antibiotic resistance and advocates the use of furazolidone, a drug which has proven to be efficient in fighting infection by H. pylori in Brazil.…”

Section: Resultsmentioning

confidence: 90%

“…In 2002, Eisig et al [7] proposed a 7-day treatment based on furazolidone and tetracycline combined to a pump inhibitor (Omeprazole) in patients that had been previously treated. Not so good rates of eradication were observed (75% by protocol and 69% with intention-to-treat), with many side effects which impeded the continued use of these medications [10].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Helicobacter Pylori Treatment with Alternative Drugs: Good and Cheap for Developing Countries Furazolidone-Based Treatment- Omeprazole, Furazolidone and Tetracycline Open-Label Trial in A Developing Country: Why Not?

Rizzuto¹,

Pasqualucci²,

Chehter³

2014

GHOA

View full text Add to dashboard Cite

a. Past or present duodenal and/or gastric ulcer, with or without complications. b. Following resection of gastric cancer. AbstractObjective: To analyze eradication rate and evaluate collateral effects of an existing alternative dosage, comprised of Omeprazole, tetracycline and furazolidone for 7 days in patients with gastric and/or duodenal ulcers and first-degree relatives of family members with a diagnosis of gastric cancer with positive study for Helicobacter pylori (H. pylori) and treatment-naive. Design and location:The out patients from the Clinic of the Gastroenterology Department of the ABC Medical School, Santo Andre, SP-Brazil. Results: 85 patients were included in the study of which 55 completed the treatment. 95% of the patients had an adequate adherence to the treatment. 49% of the patients analyzed by protocol had at least one side effect, with the most common being nausea (24%) and there was no statistical difference between the relation of side effects and lapse of treatment for H. pylori. 5% (3 patients) interrupted the treatment. The eradication rate per protocol (PP) was 96% (95%CI: 84% to 100%) for patients who completed the treatment. Patients and methods: Conclusion:The therapy based on Omeprazole, tetracycline and furazolidone in the dosages proposed represents a good and low-cost alternative to the first-line therapy to eradicate infection by H. pylori in treatment-naive patients in a developing country.

show abstract

Section: Resultssupporting

confidence: 89%

Section: Resultsmentioning

confidence: 90%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Helicobacter Pylori Treatment with Alternative Drugs: Good and Cheap for Developing Countries Furazolidone-Based Treatment- Omeprazole, Furazolidone and Tetracycline Open-Label Trial in A Developing Country: Why Not?

Rizzuto¹,

Pasqualucci²,

Chehter³

2014

GHOA

View full text Add to dashboard Cite

show abstract

“…A associação de tetraciclina, furazolidona e IBP foi incluída como forma de oferecer opção terapêutica envolvendo antimicrobianos que hoje acham-se disponíveis para a população na rede do Sistema Único de Saúde. Tal associação foi alvo de apenas um estudo nacional, onde atingiu aproximadamente, 70% de erradicação com 15% dos pacientes apresentando efeitos adversos (21) .…”

Section: Comentáriosunclassified

II Consenso Brasileiro sobre Helicobacter pylori

Coelho

Zaterka

2005

Arq. Gastroenterol.

View full text Add to dashboard Cite

INTRODUÇÃODesde sua identificação por MARSHALL e WARREN (13) , em 1982, O Helicobacter pylori (HP) rapidamente se tornou alvo de incontáveis estudos microbiológicos, histológicos, epidemiológicos, imunológicos, ecológicos e clínicos, entre outros. Conseqüentemente, em curto período de tempo, os avanços do conhecimento na área puderam ser utilizados, de forma revolucionária, na prática médica diária de clínicos e gastroenterologistas. O alcance desta descoberta pode ser avaliado pelo resultado de inquérito recente entre gastroenterologistas, onde tal descoberta foi considerada a mais importante da especialidade no último século (8) .Com o objetivo de orientar os médicos nas várias questões relacionadas ao manuseio da infecção pelo HP, diferentes reuniões de consenso têm sido realizadas em todo o mundo (1,5,10,12,15,23) . No Brasil, em 1995, durante o Congresso Panamericano de Enfermedades Digestivas, realizado em Belo Horizonte, MG, foi realizado o "Consenso Nacional sobre H. pylori e afecções associadas" (2) .A

show abstract

“…12 Previous studies with tetracycline-based regimens with adults have reported rates ranging from 34 to 59.7%, most of them mild, and the most frequent reported side effects is nausea (up to 34.6%). 18,19,27 It is interesting that the main side effect reported in the present study is abdominal pain, and it is likely that this symptom was related to the clinical condition of the patient rather than to the therapy.…”

Section: Discussionmentioning

confidence: 75%

Furazolidona, tetraciclina e omeprazol: uma alternativa de baixo custo para erradicação de Helicobacter pylori em crianças

Machado¹,

Silva²,

Viriato³

2008

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

Objectives: To evaluate furazolidone, tetracycline and omeprazole as first line therapy for Helicobacter pylori in children with digestive symptoms. Methods:Prospective and consecutive open trial. The study included patients older than 8 years old with functional dyspepsia, functional abdominal pain, severe histological abnormalities (intestinal metaplasia, gastric atrophy or mucosa-associated lymphoid tissue lymphoma) or peptic ulcer. H. pylori status was defined based both upon histology and rapid urease test. Drug regimen was a 7-day course of omeprazol, tetracycline (or doxycycline) and furazolidone twice daily. Eradication was assessed by upper endoscopy 2 months after treatment (histology and rapid urease test).Further clinical evaluation was done 7 days and 2 months after treatment.Results: Thirty-six patients (21 female/15 male) were included. Age ranged from 8 to 19 years (mean 12.94±2.89 years). On intention-to-treat analysis (n = 36), eradication rate was 83.3% (95%CI 77.1-89.5) whereas in per-protocol analysis (n = 29), it was 89.7% (95%CI 84.6-94.7). Compliance was better when doxycycline was used, but the success rates were similar for the two tetracyclines. There was no variable associated with treatment failure. Side effects were reported in 17 patients (47.2%), mainly abdominal pain (11/30.5%), nausea (seven/19.4%) and vomiting (five/ 13.9%). Conclusion:Triple therapy with furazolidone and tetracycline is a low-cost alternative regimen to treat H. pylori infection.J Pediatr (Rio J). 2008;84(2):160-165: Furazolidone, tetracycline, Helicobacter pylori treatment, child, clinical trial.

show abstract

Omeprazole, Furazolidone, and Tetracycline: an eradication treatment for resistant H. pylori in Brazilian patients with peptic ulcer disease

Abstract: The treatment provides good efficacy for H. pylori eradication in patients who were previously treated without success, but it causes severe adverse effects that prevented adequate use of the medications in 15% of the patients.

Cited by 16 publications

References 30 publications

Helicobacter Pylori Treatment with Alternative Drugs: Good and Cheap for Developing Countries Furazolidone-Based Treatment- Omeprazole, Furazolidone and Tetracycline Open-Label Trial in A Developing Country: Why Not?

Helicobacter Pylori Treatment with Alternative Drugs: Good and Cheap for Developing Countries Furazolidone-Based Treatment- Omeprazole, Furazolidone and Tetracycline Open-Label Trial in A Developing Country: Why Not?

II Consenso Brasileiro sobre Helicobacter pylori

Furazolidona, tetraciclina e omeprazol: uma alternativa de baixo custo para erradicação de Helicobacter pylori em crianças

Contact Info

Product

Resources

About